Kindred Biosciences Inc (KIN.OQ)
23 May 2018
* KINDRED BIOSCIENCES ANNOUNCES FIRST QUARTER 2018 FINANCIAL RESULTS
Kindred Biosciences Inc has received the first U.S. approval for a treatment for unintended weight loss in cats, opening the door to a market it says extends to up to 9 million potential cases in the United States alone.
May 7 Kindred Biosciences Inc has received the first U.S. approval for a treatment for unintended weight loss in cats, opening the door to a market it says extends to up to 9 million potential cases in the United States alone.
May 7 Kindred Biosciences inc said on Monday the U.S. Food and Drug Administration had approved its topical treatment for unintended weight loss in cats.
* KINDRED BIOSCIENCES SAYS ENTERED INTO AT MARKET ISSUANCE SALES AGREEMENT - SEC FILING
BRIEF-Kindred Biosciences Receives FDA Approval Of Mirataz For The Management Of Weight Loss In Cats
* KINDRED BIOSCIENCES RECEIVES FDA APPROVAL OF MIRATAZ™ (MIRTAZAPINE TRANSDERMAL OINTMENT) FOR THE MANAGEMENT OF WEIGHT LOSS IN CATS
* KINDRED BIOSCIENCES ANNOUNCES THE APPOINTMENT OF DR. ERNEST MARIO AND DR. JOSEPH MCCRACKEN TO ITS BOARD OF DIRECTORS Source text for Eikon: Further company coverage:
* KINDRED BIOSCIENCES ANNOUNCES FOURTH QUARTER AND FULL YEAR 2017 FINANCIAL RESULTS
* KINDRED BIOSCIENCES INC FILES FOR MIXED SHELF OF UP TO $150 MILLION – SEC FILING Source text - (http://bit.ly/2risHPv) Further company coverage:
* KINDREDBIO ANNOUNCES SUBMISSION OF EUROPEAN MEDICINES AGENCY FILING FOR MIRATAZ™
|Merck & Co., Inc. (MRK.N)||$59.17||+0.72|
|Bayer AG (BAYGn.DE)||€102.74||-2.30|
|Bayer AG (BAYE.F)||--||--|
|Zoetis Inc (ZTS.N)||$84.88||+0.50|
|Dechra Pharmaceuticals plc (DPH.L)||2,710.00||-40.00|
|Aratana Therapeutics Inc (PETX.OQ)||$5.39||+0.04|
|Eli Lilly And Co (LLY.N)||$82.68||+0.46|
|Sanofi SA (SASY.PA)||€66.23||-0.14|
|Nexvet Biopharma plc (NVET.OQ)||--||--|
|Jaguar Health Inc (JAGX.OQ)||$0.15||-0.00|